INSILICO Aktie

>INSILICO Aktienkurs

4.72 EUR +5.8% (TradegateBSX)

Ask: 4.88 EUR / 1024 Stück

Bid: 4.72 EUR / 1062 Stück

Tagesumsatz: 752 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INSILICO Aktie über LYNX handeln

Intraday

1 Jahr

>INSILICO Performance

1 Woche: +12,9%

1 Monat: +28,3%

3 Monate: -29,0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>INSILICO Aktie

Profil:

InSilico Medicine Cayman TopCo is an artificial intelligence-based biotechnology company focused on drug discovery and development. It leverages generative AI through its Pharma.AI platform, an end-to-end software and automation solution that enhance..
>Volltext..

Insiderhandel:

>INSILICO Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>INSILICO Peer Group

Gesundheit, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung

>INSILICO Chart & Kurs - Tradegate

>INSILICO News

13.07.26 - 02:33	Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases (PR Newswire)
	SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking......

09.07.26 - 03:30	Alert: INSILICO Expects Interim Turnaround to Profit, Earning Up to USD39.5 million (AAStocks)
	INSILICO (03696.HK) issued a positive profit alert, expecting to swing into profit for the interim period ending 30 Jun this year, with net profit ranging from approximately USD33.5 million to USD39.5 million, compared with a net loss of USD19.2 million in the same period last year. Adjusted non-IFRS net profit is expected to ra......

09.07.26 - 02:33	Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 (PR Newswire)
	CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of......

07.07.26 - 15:48	Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (PR Newswire)
	Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine Rentosertib represents a novel......

02.07.26 - 13:06	Takeda, Insilico sign AI drug discovery pact worth up to $600M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.07.26 - 12:12	Insilico Medicine, Takeda partner on AI-driven drug discovery (PBR)
	Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Takeda will take the lead in advancing selected The post Insilico Medicine, Takeda partner on AI-driven drug discovery appeared first on Pharmaceutical Business review....

02.07.26 - 05:30	Takeda and Insilico strike AI-led drug discovery deal worth up to $600m (Nikkei)
	Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

02.07.26 - 04:18	Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery (PR Newswire)
	Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic......

02.07.26 - 03:45	INSILICO Opens 10.75% Higher After Inking USD600M AI-powered Drug Discovery Strategic Partnership with Takeda (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

02.07.26 - 02:06	Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million (WSJ EN)
	Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter....

26.06.26 - 14:30	"Götter-Medikament": Dieser KI-Konzern jagt das größte Versprechen der Medizin (Wallstreet-Online)
	Der KI-Pharmaspezialist InSilico setzt auf Langlebigkeitsmedizin, Milliarden-Partnerschaften und China. Das Ziel: profitabel werden und die Branche verändern....

26.06.26 - 08:48	InSilico Is on a Mission: Be No. 1 in China, Create ‘God Drug’ With AI (WSJ EN)
	The pharma company, the first to use generative AI to develop a drug that reached clinical trials, is betting longevity treatments will fuel its next phase of growth....

22.06.26 - 07:06	Insilico partners with SK Biopharmaceuticals in $2.5B AI drug pact (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.06.26 - 06:45	INSILICO Enters R&D Collaboration with SK Biopharmaceuticals, Potential Deal Value Exceeds USD2.5 billion (AAStocks)
	INSILICO (03696.HK) announced that it has entered into a research and development collaboration with SK Biopharmaceuticals to discover AI-driven innovative drug candidates targeting central nervous system (CNS) neuroimmunology diseases.Under the collaboration, INSILICO will leverage its proprietary Pharma.AI platform, which cove......

22.06.26 - 06:39	Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders (PR Newswire)
	CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug......

17.06.26 - 15:06	Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics (PR Newswire)
	CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development......

12.06.26 - 14:54

SpaceX IPO Raises $75 Billion, US-Iran Edge Towards Interim Deal | The Pulse 6/12/2026 (Bloomberg)

"The Pulse With Francine Lacqua" is all about conversations with high profile guests in the beating heart of global business, economics, finance and politics. Based in London, we go wherever the story is, bringing you exclusive interviews and market-moving scoops. Today's guests: John Waldron, Goldman Sachs, COO & President; Konstantin Veit, PIMCO Portfolio Manager; Alex Michl, Czech Central Bank Governor; Alex Zhavoronkov, Insilico Founder; Rudolf Minsch, Economiesuisse, Chief Economist (Source: Bloomberg)...

08.06.26 - 03:30	INSILICO to Be Included in FTSE Global Equity Index Series (AAStocks)
	Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

27.05.26 - 19:46	Human Longevity′s Launched New Entity Human Life Foundation Models, Inc. and Insilico Medicine Collaborates to Build the First Foundation Model for Longevity Science (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Human Longevity, Inc. today announced the creation of a new company, Human Life Foundation Models, Inc. (HLFM), dedicated to developing large-scale foundation models for human longevity science. HLFM's first strategic collaboration......

27.05.26 - 06:30	INSILICO Clarifies No Concrete Plan for Secondary Listing at Present (AAStocks)
	INSILICO (03696.HK) issued a clarification announcement stating that the company currently has no concrete plan for a secondary listing. The company will make further announcements in a timely manner in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited upon any material deve......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Absicht eines Christen, der ein Streitgespräch über die Glaubenswahrheiten führt, muß nicht darauf zielen, den Glauben zu beweisen, sondern den Glauben zu verteidigen. - Hl. Thomas von Aquin

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram